Equities analysts expect FibroGen Inc (NASDAQ:FGEN) to announce $51.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for FibroGen’s earnings, with the highest sales estimate coming in at $119.30 million and the lowest estimate coming in at $18.60 million. FibroGen posted sales of $43.95 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 17.4%. The firm is expected to issue its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that FibroGen will report full-year sales of $237.41 million for the current fiscal year, with estimates ranging from $192.50 million to $292.00 million. For the next year, analysts anticipate that the firm will report sales of $307.65 million, with estimates ranging from $125.40 million to $505.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover FibroGen.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $20.44 million. During the same quarter in the prior year, the firm earned ($0.50) EPS. The company’s quarterly revenue was down 25.1% compared to the same quarter last year.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $36.34, for a total value of $1,440,372.24. Following the completion of the transaction, the chief executive officer now directly owns 2,527,044 shares in the company, valued at approximately $91,832,778.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $46.41, for a total transaction of $522,112.50. Following the completion of the transaction, the senior vice president now owns 163,562 shares of the company’s stock, valued at $7,590,912.42. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 220,938 shares of company stock valued at $8,908,635. 7.83% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Lindbrook Capital LLC increased its position in shares of FibroGen by 150.0% during the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 300 shares during the period. American International Group Inc. increased its position in shares of FibroGen by 1.0% during the fourth quarter. American International Group Inc. now owns 50,074 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 478 shares during the period. FTB Advisors Inc. acquired a new stake in shares of FibroGen during the first quarter worth $27,000. Chartwell Investment Partners LLC increased its position in shares of FibroGen by 1.4% during the first quarter. Chartwell Investment Partners LLC now owns 44,073 shares of the biopharmaceutical company’s stock worth $2,395,000 after buying an additional 598 shares during the period. Finally, Cornerstone Advisors Inc. increased its position in shares of FibroGen by 672.8% during the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 693 shares during the period. Hedge funds and other institutional investors own 66.27% of the company’s stock.
FGEN stock traded up $2.07 during mid-day trading on Tuesday, reaching $44.82. 385,592 shares of the stock traded hands, compared to its average volume of 765,214. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. FibroGen has a 52 week low of $33.51 and a 52 week high of $67.85. The stock has a 50-day simple moving average of $40.59. The company has a market cap of $3.82 billion, a price-to-earnings ratio of -43.51 and a beta of 1.85.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.